BIOCON I. LTD

Nature of Business: Manufacturer

Company Introduction: Biocon I. Ltd. is a leading Indian biopharmaceutical company headquartered in Bangalore, India. It is primarily engaged in the research, development, manufacturing, and marketing of biopharmaceuticals. The company's operations encompass the entire value chain from discovery and development to commercialization. Biocon produces a range of products including biosimilars, novel biologics, and small molecule APIs (Active Pharmaceutical Ingredients) for various therapeutic areas such as diabetes, oncology, and immunology. With its own state-of-the-art manufacturing facilities and a strong focus on innovation and global expansion, Biocon is recognized as a major player in the biopharmaceutical industry.

Biocon Limited, an Indian biopharmaceutical company, manufactures and sells a wide range of products primarily focused on biosimilars, novel biologics, and biopharmaceutical Active Pharmaceutical Ingredients (APIs).

Key products include biosimilars such as Insulin Glargine (for example, Basalog One, Semglee in certain markets), Recombinant Human Insulin (for example, Insugen), Trastuzumab (for example, CANMAb, Ogivri), Pegfilgrastim (for example, Fulphila), Bevacizumab biosimilar, Adalimumab biosimilar (for example, Hulio), and Insulin Aspart biosimilar (for example, Kwikpen).

The company also has a novel biologic, Itolizumab (for example, ALZUMAb), in its portfolio, used for conditions like psoriasis and, under emergency use, for COVID-19 treatment in India.

Additionally, Biocon produces APIs and finished dosage formulations for various small molecules, including immunosuppressants like Tacrolimus, Sirolimus, and Everolimus (for example, Biocimus), as well as products for diabetes (for example, Metformin) and cardiovascular diseases (for example, Statins like Rosuvastatin).